The marketing authorisation for NeoSpect has been withdrawn at the request of the marketing authorisation holder.
NeoSpect : EPAR - Summary for the public (PDF/263.04 KB)
First published: 07/11/2007
Last updated: 19/11/2010
|Agency product number||
|International non-proprietary name (INN) or common name||
|Therapeutic area (MeSH)||
|Anatomical therapeutic chemical (ATC) code||
CIS bio international
|Date of issue of marketing authorisation valid throughout the European Union||
Route Nationale 306, Saclay
28/10/2010 NeoSpect - EMEA/H/C/000263 - N/0015
- Annex I - Summary of product characteristics
- Annex IIA - Manufacturing-authorisation holder responsible for batch release
- Annex IIB - Conditions of the marketing authorisation
- Annex IIIA - Labelling
- Annex IIIB - Package leaflet
Please note that the size of the above document can exceed 50 pages.
You are therefore advised to be selective about which sections or pages you wish to print.
This medicinal product is for diagnostic use only.
For scintigraphic imaging of suspected malignant tumours in the lung after initial detection, in
combination with CT scan or chest X-ray, in patients with solitary pulmonary nodules.